Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Other Working Capital Changes: 2022-2024

Historic Other Working Capital Changes for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $218.0 billion.

  • Addex Therapeutics' Other Working Capital Changes fell 43.86% to $218.0 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.4 billion, marking a year-over-year decrease of 118.65%. This contributed to the annual value of -$186,742 for FY2024, which is 414.16% down from last year.
  • Per Addex Therapeutics' latest filing, its Other Working Capital Changes stood at $218.0 billion for Q4 2024, which was up 198.90% from -$220.4 billion recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Other Working Capital Changes ranged from a high of $440.0 billion in Q3 2023 and a low of -$815.3 billion during Q2 2023.
  • Moreover, its 3-year median value for Other Working Capital Changes was $234,947 (2022), whereas its average is $880.9 million.
  • Within the past 5 years, the most significant YoY rise in Addex Therapeutics' Other Working Capital Changes was 68,350,272.57% (2023), while the steepest drop was 704,782,990.52% (2023).
  • Over the past 3 years, Addex Therapeutics' Other Working Capital Changes (Quarterly) stood at $568,070 in 2022, then spiked by 68,350,272.57% to $388.3 billion in 2023, then plummeted by 43.86% to $218.0 billion in 2024.
  • Its last three reported values are $218.0 billion in Q4 2024, -$220.4 billion for Q3 2024, and $354,209 during Q2 2024.